Merck Sharpens Late Stage Drug Development Focus — Shedding Migraine Candidates

Kenilworth will receive $250 million — and additional revenue, if milestones are met — from Allergan, the acquirer here.

Per The Wall Street Journal reporting then:

. . . .Allergan PLC said Tuesday that it has reached a deal to buy the exclusive world-wide rights to two of Merck & Co.’s experimental migraine drugs for an upfront payment of $250 million.

Merck could also receive milestone and royalty payments based on commercialization of the two calcitonin gene-related peptide (CGRP) receptor antagonists, which are being developed for treatment and prevention of migraines. . . .

In the event that the candidate(s) clear FDA, Merck will also get a running royalty payment on each sale. But do recall that in 2009, and in 2011, Merck saw a liver toxicity signal in a Phase II trial of one of its other CGRP class candidates, so the future of these two is not entirely clear. Thus far neither of these current two harbor any class effect, thankfully though. For its part, Allergan may be able to broaden its reach — and move into larger arenas — outside of the cosmetic surgery suites, in consumer health care. Onward — on a cool cloudy but nonetheless cheerful Tuesday.

Advertisements

There are no comments on this post.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: